Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform. Our method is widely applicable across drug classes and modalities. We specifically apply our approach to challenging oncology drug targets causally implicated in the vast majority of cancers, particularly those without simple single gene driver mutations or synthetic lethal contexts. Leveraging our unique patient selection platform, Acrivon Therapeutics aims to rapidly progress in-licensed clinical-stage assets and a pipeline of internally developed programs through accelerated registration trials. Acrivon Therapeutics and its clinical biomarker development group is headquartered in the greater Boston area, with biomarker discovery efforts concentrated in our wholly-owned subsidiary in Lund, Sweden.
Acrivon Therapeutics Address
480 Arsenal Way Cambridge, MA United States
Acrivon Therapeutics Email
Past Companies
Acrivon Therapeutics, Inc.VP, Head of Data Science
TheonysVP, Data Science & Head of Translational Sciences
CyclerionHead of Informatics and Translational Science Lead